Literature DB >> 15681900

A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.

Kaori Morimoto1, Tomoharu Oishi, Shiro Ueda, Madoka Ueda, Masakiyo Hosokawa, Kan Chiba.   

Abstract

We have recently found that the frequency of OATP-C*15 is significantly higher in patients who experienced myopathy after receiving pravastatin or atorvastatin than in patients without myopathy. However, there were two patients who experienced pravastatin-induced myopathy despite the fact that they did not possess OATP-C*15 or other known mutations of OATP-C that have been reported to decrease the function of OATP-C. In this study, we sequenced all of the exons and exon-intron junctions of OATP-C of the two patients and found a novel mutation in exon 12 of OATP-C in one of the patients. In this mutation (1628T>G), there is a substitution of Leu to Trp at position 543 in transmembrane-spanning domain 10 of OATP-C. However, the frequency of this mutation in the Japanese population appears to be very low (<1%).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15681900     DOI: 10.2133/dmpk.19.453

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  20 in total

1.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

Authors:  Evita van de Steeg; Els Wagenaar; Cornelia M M van der Kruijssen; Johanna E C Burggraaff; Dirk R de Waart; Ronald P J Oude Elferink; Kathryn E Kenworthy; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 2.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

Review 3.  Pharmacogenomics of human OATP transporters.

Authors:  Jörg König; Annick Seithel; Ulrike Gradhand; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-09       Impact factor: 3.000

4.  Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport.

Authors:  Chunshan Gui; Bruno Hagenbuch
Journal:  Biochemistry       Date:  2008-08-09       Impact factor: 3.162

Review 5.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

6.  Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1.

Authors:  Chunshan Gui; Bruno Hagenbuch
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

Review 7.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 8.  Mechanisms and assessment of statin-related muscular adverse effects.

Authors:  Dirk Moßhammer; Elke Schaeffeler; Matthias Schwab; Klaus Mörike
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

9.  Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.

Authors:  Annick Seithel; Kathrin Klein; Ulrich M Zanger; Martin F Fromm; Jörg König
Journal:  Mol Genet Genomics       Date:  2007-11-08       Impact factor: 3.291

10.  Pharmacogenomic insights into treatment and management of statin-induced myopathy.

Authors:  Bas Jm Peters; Olaf H Klungel; Frank L Visseren; Anthonius de Boer; Anke-Hilse Maitland-van der Zee
Journal:  Genome Med       Date:  2009-12-29       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.